Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Unknown 2

Sponsor Class

OTHER 490INDUSTRY 216NIH 17NETWORK 13OTHER_GOV 10UNKNOWN 2FED 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Breast 1

Conditions

Breast Neoplasms 21Stomach Neoplasms 14Colorectal Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Rectal Neoplasms 7Triple Negative Breast Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Small Cell Lung Carcinoma 4Lymphoma, Extranodal NK-T-Cell 4Esophageal Squamous Cell Carcinoma 4Esophageal Neoplasms 4Brain Neoplasms 4Neoplasms 3Neoplasm Metastasis 3Head and Neck Neoplasms 3Vomiting 2Sarcoma 2Recurrence 2Nasopharyngeal Carcinoma 2Lymphoma, Large B-Cell, Diffuse 2Lung Neoplasms 2HER2-positive Breast Cancer 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Lung 1Radiation Injuries 1Platinum-resistant Recurrent Ovarian Cancer 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pain 1Ovarian Neoplasms 1

Interventions

Rituximab 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × UNKNOWN × Recurrence × Clear all
NCT04994626 2021-08-06

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

ChineseAMS

Phase 2 Unknown
20 enrolled
Lymphoid

Lymphoma, Recurrence

NCT01492556 2013-03-15

Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast Cancer

ChineseAMS

Phase 2 Unknown
100 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡